Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | Changing opinions on the use of biosimilars

Matti Aapro • 8 Sep 2017

Matti Aapro, MD, from the Multidisciplinary Oncology Institute, Genolier, Switzerland, discusses misconceptions by healthcare professionals about biosimilars at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Registration for biosimilars is quite a complex process, and to be approved, they must prove that they are the same product as the originator. Using biosimilars reduces the cost, therefore increasing the availability and accessibility. There are still some misunderstandings about biosimilars, however, with more information, this will change.